FOXO TECHNOLOGIES INC. Accrued Liabilities for Commissions, Expense and Taxes
FOXO TECHNOLOGIES INC. (FOXO) had Accrued Liabilities for Commissions, Expense and Taxes of $620.00 thousand as of 2023-09-30, per its 10-Q/A filed 2024-06-04.
Discontinued › Notes › Insurance
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2024-06-06
- 2023-09-30: Accrued Liabilities for Commissions, Expense and Taxes $620.00K.
- 2023-06-30: Accrued Liabilities for Commissions, Expense and Taxes $740.00K.
- 2023-03-31: Accrued Liabilities for Commissions, Expense and Taxes $879.00K.
- 2022-12-31: Accrued Liabilities for Commissions, Expense and Taxes $999.00K.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2023-09-30 | $620.00K 10-Q/A · filed 2024-06-04 |
| 2023-06-30 | $740.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $879.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $999.00K 10-K · filed 2024-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |